[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"salivary-gland-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:salivary-gland-carcinoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100527249","phase-2-precision-treatment-of-recurrentmetastatic-salivary-gland-carcinoma-guided-by-molecular-typing-100527249",false,"NCT06145308","Precision Treatment of Recurrent\u002FMetastatic Salivary Gland Carcinoma Guided by Molecular Typing","Cancer Hospital, Chinese Academy of Medical Sciences\u002FNational Cancer Center of China","Inclusion Criteria:\n\n* Patients with histopathologic diagnosis of salivary gland carcinoma\n\n  * The tumor tissues were subjected to HER2\u002FNTRK\u002FAR\u002FTROP-2 immunohistochemical staining.\n\n    * ECOG physical status 0 or 1 score in the 3 days before the first medication of the study treatment;\n\n      * Age 18 or older - no upper limit;\n\n        * Life expectancy is more than 3 months; ⑥Have at least one measurable lesion according to RECIST1.1 standards; ⑦Women of childbearing age must have a negative pregnancy test within 7 days before the first medication, and agree to receive the necessary contraceptive measures;\n\n          ⑧The patient must have adequate liver, kidney, bone marrow, heart and lung and other organ functions:\n\n          ⑨Understanding and voluntarily signing informed consent prior to performing any research-related evaluation\u002Foperation;\n\n          ⑩Ability to comply with research visit schedules and other programmatic requirements.\n\nExclusion Criteria:\n\n* Known hypersensitivity or delayed anaphylaxis to any agents in this trial;\n\n  * Major surgery had been performed within 4 weeks prior to the start of the study and did not fully recover;\n\n    * Have received a live vaccine within 4 weeks before the start of the study or plan to receive any vaccine during the study period ;\n\n      * To study the occurrence of arterial\u002Fvenous thrombosis events within 6 months before medication;\n\n        * Major cardiovascular diseases;\n\n          * Is suffering from uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, acute lung disease, interstitial lung disease, cirrhosis, etc.;\n\n            * Is suffering from an active infection that requires systemic treatment;\n\n              * History of active tuberculosis; ⑨ Positive human immunodeficiency virus (HIV) test result; ⑩ Patients with chronic hepatitis B or active hepatitis C. ⑪Conditions that the investigator believes will affect the safety or compliance of the drug therapy in this study ⑫Female\u002Fmale who is pregnant or breastfeeding or who intends to give birth;","ALL","18 Years","100 Years",{"count":20,"type":21},39,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate) and safety of precision therapy.",[27,28],"Salivary Gland Carcinoma","Precision Therapy","RECRUITING","2026-03-27",{"date":32,"type":33},"2026-04-02","ACTUAL",{"date":35,"type":33},"2023-08-15",{"date":37,"type":21},"2028-07-10",{"name":39,"class":40},"Peking Union Medical College","OTHER",2]